- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Alagille syndrome (ALGS)
- Meeting Date: March 2026
Odevixibat – March 2026
Capsule 200 micrograms, Capsule 400 micrograms, Capsule 600 micrograms, Capsule 1200 micrograms
Public Summary Documents
Last updated
11 March 2026
